RALEIGH, N.C., March 13, 2018 /PRNewswire/ -- Arrevus Inc., a biotechnology company developing chaperone protein inhibitors to combat antimicrobial resistance, announced the addition of three new board members: Barry Garfinkle, Joe McMahon, and Joe St. Geme. "We feel privileged to have the depth of experience and guidance available to us with the appointments of each of our new Board members. Arrevus is well-poised to continue developing novel solutions to the growing threat of antibiotic-resistant infections," said Carl N. Kraus, M.D., President and CEO of Arrevus.
Barry D. Garfinkle, Ph.D., is the Principal of Garfinkle & Associates Consulting. Formerly the Vice President of Biological Sciences and Strategy at Merck, Dr. Garfinkle has served on the USP Council of Experts, first on the Microbiology Committee and then as Chair of the Vaccine and Virology Committee. Dr. Garfinkle has also provided training to the U.S. FDA in microbiology and was a member of the Pharmaceutical Manufacturers Association.
Joe McMahon is currently CEO of Bioventure Partners, providing growth advisory services and investments to high-impact, technology-driven companies in the life science and medical device sectors. Mr. McMahon was the former President and CEO of both KBI Biopharma and kSep Systems. KBI is a global contract development and manufacturing organization serving the biopharmaceutical industry and was acquired by JSR Corporation in 2015. kSep Systems, a spin-out of KBI Biopharma, was acquired by Sartorius, AG in 2016.
Joe St. Geme, M.D., is the Physician-in-Chief and Chairman of the Department of Pediatrics at Children's Hospital of Philadelphia and Chairman of the Department of Pediatrics at the University of Pennsylvania. He is a Professor of Pediatrics and Microbiology and a member of the Microbiology, Virology, and Parasitology Program at the University of Pennsylvania. He previously served as the Director of Pediatric Infectious Diseases at Washington University in St. Louis, MO. Dr. St. Geme's laboratory is focusing on bacterial pathogenesis and characterizing common protein secretion pathways as targets for new antimicrobials with activity against pathogenic gram-negative bacteria.
Arrevus is a biotechnology company whose mission is to eliminate the threat of antibiotic resistance and improve treatment outcomes for serious infectious diseases. Arrevus is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs). Arrevus has its headquarters in Raleigh, NC. For more information about Arrevus Inc., visit www.arrevus.com or email [email protected].